National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
9
760K
9
5
- Areas of investment
Summary
The important activity for fund was in 2019. Considering the real fund results, this Corporate Investor is 47 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 100 thousands - 1 million dollars. The fund is constantly included in less than 2 investment rounds annually.
The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), startups are often financed by Bios Partners, Washington Research Foundation., National Cancer Institute SBIR Development Center. The meaningful sponsors for the fund in investment in the same round are National Institutes of Health. In the next rounds fund is usually obtained by U.S. Department of Defense, National Science Foundation, KdT Ventures.
Among the most successful fund investment fields, there are Health Care, Alternative Medicine. Among the most popular portfolio startups of the fund, we may highlight Azitra. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
Investments analytics
Analytics
- Total investments
- 9
- Lead investments
- 5
- Investments by industry
- Biotechnology (7)
- Health Care (7)
- Life Science (2)
- Health Diagnostics (2)
- Therapeutics (2) Show 13 more
- Investments by region
-
- United States (9)
- Peak activity year
- 2023
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Group Appearance index
- 0.33
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.